Advertisement

Drugs

, Volume 70, Issue 4, pp 455–467 | Cite as

Pilsicainide

  • Greg L. Plosker
Adis Drug Profile

Abstract

Pilsicainide is a class Ic antiarrhythmic agent used for the treatment of supraventricular and ventricular tachycardia. The pharmacodynamic effects of pilsicainide are achieved via selective sodium channel blockade.

In randomized, multicentre trials in patients with atrial fibrillation, restoration of sinus rhythm was achieved in significantly more patients treated with a single oral dose of pilsicainide than those who received placebo, and in a numerically higher proportion of oral pilsicainide than intravenous dis-opyramide recipients.

In another well designed trial in patients with persistent atrial fibrillation, the proportion of patients whose arrhythmia converted to normal sinus rhythm was significantly higher among those randomized to receive 2 weeks of oral pilsicainide therapy than among patients who received placebo.

Over a 1-year period, both pilsicainide and cibenzoline (another class Ic agent) were effective in preventing recurrence of atrial fibrillation in a substantial proportion of patients in a single-centre crossover trial. There were no between-group differences in the subgroup of patients with shorter-duration atrial fibrillation, but actuarial results over 1 year significantly favoured cibenzoline over pilsicainide in patients with longer-duration atrial fibrillation.

Both oral and intravenous pilsicainide have demonstrated efficacy in ventricular tachyar-rhythmias, including ventricular extrasystole.

Clinical trial and postmarketing surveillance data indicate that pilsicainide is generally well tolerated in most patients.

Keywords

Atrial Fibrillation Sinus Rhythm Disopyramide Flecainide Atrial Flutter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements and Disclosures

The manuscript was reviewed by: J.R. Ehrlich, Division of Cardiology, Goethe-University, Frankfurt, Germany; T. Watanabe, First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, Japan.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes based on any comments received were made on the basis of scientific and editorial merit.

References

  1. 1.
    Tachycardia: diagnosis and treatment at Mayo Clinic [online]. Available from URL: http://www.mayoclinic.org/tachycardia/[Accessed 2010 Jan 14]
  2. 2.
    Fox DJ, Tischenko A, Krahn AD, et al. Supraventricular tachycardia: diagnosis and management. Mayo Clin Proc 2008 Dec; 83(12): 1400–11PubMedCrossRefGoogle Scholar
  3. 3.
    Clarke JM, Hamer J, Shelton JR. The rhythm of the normal human heart. Lancet 1976; 1(7984): 508–12PubMedCrossRefGoogle Scholar
  4. 4.
    Hinkle Jr LE, Carver ST, Stevens M. The frequency of asymptomatic disturbances of cardiac rhythm and conduction in middle-aged men. Am J Cardiol 1969; 24(5): 629–50PubMedCrossRefGoogle Scholar
  5. 5.
    Fuster V, Rydén LE, Crijns HJ, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation 2006; 114: e257–354PubMedCrossRefGoogle Scholar
  6. 6.
    Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs 2009; 69(7): 757–74PubMedCrossRefGoogle Scholar
  7. 7.
    Hancox JC, Patel KCR, Jones JV. Antiarrhythmics-from cell to clinic: past, present, and future. Heart 2000; 84: 14–24PubMedCrossRefGoogle Scholar
  8. 8.
    Walker MJA. Antiarrhythmic drug research. Br J Pharmacol 2006; 147: S222–31PubMedCrossRefGoogle Scholar
  9. 9.
    Hattori Y, Hidaka T, Aisaka K, et al. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles. JCardiovasc Pharmacol 1988 Apr; 11(4): 407–12CrossRefGoogle Scholar
  10. 10.
    Sunrythm® (pilsicainide 25 mg and 50 mg capsules): Japanese prescribing information [in Japanese]. Tokyo: Daiichi Sankyo, 2007Google Scholar
  11. 11.
    Hattori Y, Inomata N, Aisaka K, et al. Electrophysiological actions of N-(2,6-dimethylphenyl)8-pyrrolizidine-acetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol 1986; 8(5): 998–1002PubMedCrossRefGoogle Scholar
  12. 12.
    Inomata N, Ishihara T, Akaike N. SUN 1165: a new antiarrhythmic Na current blocker in ventricular myocytes of guinea-pig. Comp Biochem Physiol C 1987; 87(2): 237–43PubMedCrossRefGoogle Scholar
  13. 13.
    Sakai R, Inoue D, Ishibashi K, et al. Kinetics of frequency-dependent conduction delay by class I antiarrhythmic drugs in human atrium. J Cardiovasc Pharmacol 1995; 25(6): 953–60PubMedCrossRefGoogle Scholar
  14. 14.
    Hattori Y, Inomata N. Modes of the Na channel blocking action of pilsicainide, a new antiarrhythmic agent, in cardiac cells. Jpn J Pharmacol 1992 Apr; 58(4): 365–73PubMedCrossRefGoogle Scholar
  15. 15.
    Aisaka K, Hidaka T, Inomata N, et al. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165): a new potent and long-acting antiarrhythmic agent. Arzneimittelforschung 1985; 35(8): 1239–45PubMedGoogle Scholar
  16. 16.
    Hashimoto K, Ishii M, Komori S, et al. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165. Heart Vessels 1985 Feb; 1(1): 29–35PubMedCrossRefGoogle Scholar
  17. 17.
    Iwasa A, Okumura K, Tabuchi T, et al. Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. Eur J Pharmacol 1998 Aug 28; 356(1): 31–40PubMedCrossRefGoogle Scholar
  18. 18.
    Kojima J, Niwano S, Moriguchi M, et al. Effect of pilsicainide on atrial electrophysiologic properties in the canine rapid atrial stimulation model. Circ J 2003 Apr; 67(4): 340–6PubMedCrossRefGoogle Scholar
  19. 19.
    Kawase A, Ikeda T, Nakazawa K, et al. Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria. Circulation 2003; 107: 905–10PubMedCrossRefGoogle Scholar
  20. 20.
    Ino T, Atarashi H, Kuruma A, et al. Electrophysiologic and hemodynamic effects of a single oral dose of pilsicainide hydrochloride, a new class 1c antiarrhythmic agent. J Cardiovasc Pharmacol 1998 Jan; 31(1): 157–64PubMedCrossRefGoogle Scholar
  21. 21.
    Terazawa T, Suzuki M, Goto T, et al. Suppressive effect of SUN1165 on supraventricular tachycardia. Am Heart J 1991 May; 121(5): 1437–44PubMedCrossRefGoogle Scholar
  22. 22.
    Kanemoto M, Shimizu A, Yamagata T, et al. Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide. Cardiovasc Drugs Ther 2004 Jul; 18(4): 295–303PubMedCrossRefGoogle Scholar
  23. 23.
    Sadanaga T, Ogawa S. Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent. J Am Coll Cardiol 1994 May; 23(6): 1378–81PubMedCrossRefGoogle Scholar
  24. 24.
    Hirose M, Ohkubo Y, Takano M, et al. Mechanisms of the preventive effect of pilsicainide on atrial fibrillation originating from the pulmonary vein. Circ J 2007 Nov; 71(11): 1805–14PubMedCrossRefGoogle Scholar
  25. 25.
    Horiuchi D, Iwasa A, Sasaki K, et al. Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect. Eur J Pharmacol 2009 Apr 17; 608: 54–61PubMedCrossRefGoogle Scholar
  26. 26.
    Kumagai K, Tojo H, Noguchi H, et al. Effects of the Na+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2004 Dec; 15(12): 1396–401PubMedCrossRefGoogle Scholar
  27. 27.
    Kumagai K, Nakashima H, Tojo H, et al. Pilsicainide for atrial fibrillation. Drugs 2006; 66(16): 2067–73PubMedCrossRefGoogle Scholar
  28. 28.
    Sunrythm® (pilsicainide 50 mg injection): Japanese prescribing information [in Japanese]. Tokyo: Daiichi Sankyo, 2007Google Scholar
  29. 29.
    Tsuruoka S, Ioka T, Wakaumi M, et al. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther 2006 Apr; 79(4): 389–96PubMedCrossRefGoogle Scholar
  30. 30.
    Kim BH, Kim JR, Lim KS, et al. An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects. Clin Ther 2009 Mar; 31(3): 609–18PubMedCrossRefGoogle Scholar
  31. 31.
    Fukumoto K, Tanemura M, Tsuchishita Y, et al. Effect of protein binding of pilsicainide on the pharmacokinetics. Drug Metab Pharmacokinet 2005 Jun; 20(3): 183–6PubMedCrossRefGoogle Scholar
  32. 32.
    Ogawa R, Kishi R, Mihara K, et al. Population pharm-acokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. J Clin Pharmacol 2006 Jan; 46(1): 59–68PubMedCrossRefGoogle Scholar
  33. 33.
    Matsumoto M, Fujii Z, Kawata Y, et al. Appropriate dosing of pilsicainide hydrochloride in patients on hemodialysis. Nephron 2001 Jun; 88(2): 134–7PubMedCrossRefGoogle Scholar
  34. 34.
    Atarashi H, Inoue H, Hiejima K, et al. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation): the PSTAF Investigators. Am J Cardiol 1996 Sep 15; 78(6): 694–7PubMedCrossRefGoogle Scholar
  35. 35.
    Nagai S, Takeishi Y, Kubota I. Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation [letter]. Cardiovasc Drugs Ther 2003 Jan; 17(1): 95–7PubMedCrossRefGoogle Scholar
  36. 36.
    Okishige K, Fukunami M, Kumagai K, et al. Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II [published erratum appears in Circ J 2006 Jul; 70 (7): 945]. Circ J 2006 Jun; 70(6): 657–61PubMedCrossRefGoogle Scholar
  37. 37.
    Komatsu T, Tachibana H, Sato Y, et al. A randomized study on the efficacy of intravenous cibenzoline and pilsicainide administered prior to electrical cardioversion in patients with lone paroxysmal and persistent atrial fibrillation. J Cardiol 2009 Feb; 53(1): 35–42PubMedCrossRefGoogle Scholar
  38. 38.
    Kohno K, Takeuchi Y, Gomi A, et al. Efficacy and safety of a single oral dose of pilsicainide in supraventricular arrhythmia after coronary artery bypass grafting [in Japanese]. Jpn J Thorac Cardiovasc Surg 1998; 46(4): 361–7PubMedCrossRefGoogle Scholar
  39. 39.
    Kumagai K, Abe H, Hiraki T, et al. Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. Pacing Clin Electrophysiol 2000 Nov; 23 (11 Pt 2): 1880–2PubMedGoogle Scholar
  40. 40.
    Komatsu T, Sato Y, Tachibana H, et al. Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy. Circ J 2006 Jun; 70(6): 667–72PubMedCrossRefGoogle Scholar
  41. 41.
    Tojo H, Kumagai K, Noguchi H, et al. Hybrid therapy with pilsicainide and pulmonary vein isolation for atrial fibrillation. Circ J 2005 Dec; 69(12): 1503–7PubMedCrossRefGoogle Scholar
  42. 42.
    Hirao K, Okishige K, Yamamoto N, et al. Long-term efficacy of hybrid pharmacologic and ablation therapy in patients with pilsicainide-induced atrial flutter. Clin Cardiol 2005 Jul; 28(7): 338–42PubMedCrossRefGoogle Scholar
  43. 43.
    Ikeda K, Kanaya T, Yamaki M, et al. Clinical efficacy of pilsicainide (Sunrythm) in patients with non-sustained ventricular tachycardia or repetitive ventricular premature contractions [in Japanese]. Ther Res 2000; 21(3): 645–52Google Scholar
  44. 44.
    Matsumoto K, Takabatake Y, Matsuo H, et al. Efficacy and safety of antiarrhythmic agent pilsicainide hydrochloride on ventricular arrhythmias: Saitama multi center study [in Japanese]. Ther Res 1995; 16(10): 407–15Google Scholar
  45. 45.
    Niitani H, Katoh K, Sugimoto T, et al. Clinical evaluation of pilsicainide hydrochloride (SUN 1165) in patients with supraventricular premature contractions: a multicenter double-blind dose finding study [in Japanese]. Jpn J Clin Pharmacol Ther 1992; 23(3): 557–72CrossRefGoogle Scholar
  46. 46.
    Okishige K, Nishizaki M, Azegami K, et al. Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study [abstract]. Am Heart J 2000 Sep; 140(3): e1 3CrossRefGoogle Scholar
  47. 47.
    Chinushi M, Komura S, Izumi D, et al. Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome. Pacing Clin Electrophysiol 2007 May; 30(5): 662–71PubMedCrossRefGoogle Scholar
  48. 48.
    Haghi D, Schumacher B. Current management of symptomatic atrial fibrillation. Am J Cardiovasc Drugs 2001; 1(2): 127–39PubMedCrossRefGoogle Scholar
  49. 49.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 Aug 10; 321(6): 406–12CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations